These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23175594)

  • 1. Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model.
    Zinner SH; Gilbert D; Greer K; Portnoy YA; Firsov AA
    J Antimicrob Chemother; 2013 Apr; 68(4):881-7. PubMed ID: 23175594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
    Strukova EN; Portnoy YA; Zinner SH; Firsov AA
    J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment.
    Firsov AA; Strukova EN; Portnoy YA; Shlykova DS; Zinner SH
    Int J Antimicrob Agents; 2015 Sep; 46(3):313-8. PubMed ID: 26297633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model.
    Firsov AA; Gilbert D; Greer K; Portnoy YA; Zinner SH
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1223-8. PubMed ID: 22203591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
    Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models.
    Strukova EN; Portnoy YA; Romanov AV; Edelstein MV; Zinner SH; Firsov AA
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1208-15. PubMed ID: 26643328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations.
    Firsov AA; Portnoy YA; Strukova EN; Shlykova DS; Zinner SH
    Int J Antimicrob Agents; 2014 Oct; 44(4):301-5. PubMed ID: 25218155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species differences in ciprofloxacin resistance among Gram-negative bacteria: can "anti-mutant" ratios of the area under the concentration-time curve to the MIC be achieved clinically?
    Strukova EN; Portnoy YA; Zinner SH; Firsov AA
    J Chemother; 2017 Dec; 29(6):351-357. PubMed ID: 28587559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations.
    Firsov AA; Strukova EN; Shlykova DS; Portnoy YA; Kozyreva VK; Edelstein MV; Dovzhenko SA; Kobrin MB; Zinner SH
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4956-62. PubMed ID: 23896481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S; Ge Y; Livermore DM
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.
    Zinner SH; Lubenko IY; Gilbert D; Simmons K; Zhao X; Drlica K; Firsov AA
    J Antimicrob Chemother; 2003 Oct; 52(4):616-22. PubMed ID: 12951352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model.
    Firsov AA; Alieva KN; Strukova EN; Golikova MV; Portnoy YA; Dovzhenko SA; Kobrin MB; Romanov AV; Edelstein MV; Zinner SH
    J Antimicrob Chemother; 2017 Nov; 72(11):3100-3107. PubMed ID: 28981793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa.
    Rees VE; Bulitta JB; Nation RL; Tsuji BT; Sörgel F; Landersdorfer CB
    J Antimicrob Chemother; 2015 Mar; 70(3):818-26. PubMed ID: 25381167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].
    Liu MT; Sheng MY; Zhang Y; Li Y
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1427-31. PubMed ID: 21756818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.